Table 1 Pretreatment clinical characteristics

Patients (n)

30

Age (yr.)

  Median (mean)

68 (65.9)

  Range

52-76

ECOG

30 (100%)

  0

Prostate specific antigen (ng/ml)

  Median (mean)

25.8 (43.2)

  Range

2.1-293.0

Gleason score at diagnosis

  6

3 (10.0%)

  7

14 (46.7%)

  8

6 (20.0%)

  9

7 (23.3%)

Clinical stage

  T2c

2 (6.7%)

  T3a

6 (20.0%)

  T3b

21 (70.0%)

  T4

1 (4.3%)

Kattan score

  Median (mean)

172 (171)

  Range

125-200

Probability of 5-year bRFS (%)

  Median (mean)

10 (10)

  Range

0-55